Cartesian Therapeutics, Inc. 8-K

What Happened

• Cartesian Therapeutics, Inc. filed an 8-K on May 26, 2026 announcing a Loan and Security Agreement providing senior secured term loans of up to $150.0 million and the pending resignation of its Chief Medical Officer, Dr. Milos Miljkovic, effective May 31, 2026.
• The loan closes with a $50.0 million first tranche funded on May 22, 2026; additional tranches totalling up to $100.0 million are available subject to milestone and lender conditions. The company also issued a press release and updated corporate slides attached to the filing.

Key Details

• Loan facility structure: up to $150.0M total — $50.0M funded at closing; $25.0M available 1/1/27–12/1/27 (milestone-conditioned); $25.0M available 1/1/28–6/1/28 (milestone-conditioned); up to $50.0M discretionary.
• Economics & term: matures June 1, 2030; interest = greater of 8.95% or prime + 2.20%; monthly interest payments; amortization begins July 1, 2029 with monthly principal+interest payments.
• Conversion & dilution: lenders may convert up to $15.0M of outstanding principal into common stock or qualifying financing securities (conversion price $8.2526/share for common stock); early conversions limited to $5.0M before the first anniversary; conversion ownership caps apply (9.985% beneficial cap, waivable; 19.99% aggregate cap).
• Covenants & security: loans are senior secured by a first-priority lien on substantially all assets (excluding IP); financial covenants include a minimum unrestricted cash requirement (tested when market cap < $750M) beginning April 1, 2027 and a minimum trailing 3-month net product revenue covenant of $40.0M starting January 1, 2029. The company agreed to file a resale registration statement for conversion shares on request.

Why It Matters

• Liquidity: The $50M funded initial tranche provides immediate cash runway, while up to $100M more is available if Cartesian meets specified clinical, approval, sales, and financing milestones — important for financing ongoing development and commercialization plans.
• Dilution & capital structure: The lenders’ conversion feature (up to $15M) creates a potential source of equity dilution at a defined conversion price, and the loan is senior secured — rank priority that could affect creditors and equity holders in stressed scenarios.
• Operating constraints: The facility imposes covenants (cash and revenue tests, restrictions on indebtedness, asset sales, etc.) that may limit flexibility and tie certain cash and growth metrics to lender requirements; the revenue covenant starting in 2029 signals expectations for material product sales by that time.
• Management change: The CMO’s departure (effective May 31, 2026) with severance/COBRA benefits and a release of claims will be a near-term personnel change investors should note for clinical leadership continuity.

Exhibits referenced in the filing include the loan agreement, press release and corporate slide deck.